Spero Therapeutics SPRO 深 滬
已收盤 08-07 16:00:00 美东时间
1.26
-0.010
-0.79%
華盛通- 最 高1.2795
- 今 開1.27
- 成交量 45.90万股
- 最 低 1.24
- 昨 收 1.27
- 總市值 7295.59万
- 52周最高 3.08
- 市盈率 靜 8.68
- 換手率 0.79%
- 52周最低 1.08
- 委 比 38.13%
- 總股本 5790.15万
- 歷史最高 23.639
- 量 比 0.51
- 振 幅 3.11%
- 歷史最低 0.5052
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics (Nasdaq: SPRO) announced it will report its second-quarter 2026 financial results on August 12, 2026, after market close. Management will host a conference call and live webcast at 5:00 pm EDT to discuss the results and provide updates. The call can be accessed via phone or webcast links provided. Spero, a clinical-stage biopharmaceutical company, focuses on advancing next-generation medicines in immunology and inflammation.
08-04 20:01
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dr. Debra Jeske Zack, a seasoned immunologist with over 25 years of experience, has been appointed as Spero Therapeutics' Chief Medical Officer. Her expertise will strengthen the company's clinical leadership as it advances SP001, a Phase 2-ready third-generation anti-CD40L antibody targeting IgG4-related disease and other immune-mediated conditions. Dr. Zack's leadership is expected to accelerate the development of innovative therapies for patie...
07-27 12:00
信达生物早盘涨逾5% 与公司Spero就IBI355达成独家许可协议
信达生物（01801）早盘涨逾5%，截至发稿，股价上涨4.72%，现报94.30港元，成交额4.17亿港元。 7月14日，据信达生物官微消息，公司与Spe...
07-15 09:44
港股异动 | 生物医药概念盘初普升，昭衍新药升近12%，科伦博泰生物升近6%
生物医药概念盘初普升，昭衍新药升近12%，上半年纯利最高同比预增1377%；截至发稿，科伦博泰生物升近6%，信达生物升逾4%>>
07-15 09:41
Spero inks $105M financing deal with KKR affiliate
Spero Therapeutics (SPRO) said that it secured $105M in non-recourse, non-dilutive financing from affiliates of Healthcare Royalty, a business of KKR (KKR). The proceeds will primarily fund the Phase ...
07-14 18:33
Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments, t...
07-14 18:09
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Spero Therapeutics and Innovent Biologics have entered into an exclusive license agreement for SP001 (IBI355), a third-generation anti-CD40L antibody. Spero gains global rights (excluding Greater China) to develop, manufacture, and commercialize SP001, while Innovent receives an upfront payment of approximately $1.1 billion and tiered royalties. Spero plans to initiate a Phase 2 trial for IgG4-related disease in Q2 2027, while Innovent aims to st...
07-14 10:00
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of Smith & Wesson Brands Inc (NASDAQ:SWBI) rose sharply in pre-market trading as the company posted better-than-expected fourth-quarter results after Wednesday’s closing bell. Smith & Wesson reported quarterly earnings of 36 cents per share, which beat the analyst estimate of 23 cents. Quarte...
06-18 18:10
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
GSK plc (NYSE:GSK) and Spero Therapeutics, Inc. (NASDAQ:SPRO) announced on Wednesday that the U.S. Food and Drug Administration has approved Utebzi (tebipenem pivoxil hydrobromide), an oral antibiotic for adults with complicated urinary tract infections (cUTIs). First Oral Carbapenem Approved For Th...
06-18 01:29
